AIP
PFE icon

ARS Investment Partners’s Pfizer PFE Stock Holding History

ARS Investment Partners’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-559,685
Closed -$18.8M – 147
2018
Q1 		$18.8M Buy
559,685
+105,208
+23% +$3.62M 2.31% 14
2017
Q4 		$15.6M Buy
454,477
+262
+0.1% +$8.93K 1.89% 21
2017
Q3 		$15.4M Buy
454,215
+42,729
+10% +$1.37M 1.98% 16
2017
Q2 		$13.1M Buy
411,486
+3,683
+0.9% +$116K 1.81% 21
2017
Q1 		$13.2M Buy
407,803
+175,691
+76% +$5.54M 1.92% 20
2016
Q4 		$7.15M Buy
+232,112
New +$7.09M 1.1% 29

Other funds holding PFE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ARS Investment Partners's PFE Position: Q2 2018 in Review

ARS Investment Partners sold out of Pfizer (PFE) in Q2 2018, closing a stake of 559,685 shares — an estimated $18.8M sold.

ARS Investment Partners first reported a position in PFE in Q4 2016 and held it in 6 quarters. The position peaked at $18.8M in Q1 2018. 2,204 funds tracked by Wall St. Rank hold PFE as of Q2 2018.

  • ARS Investment Partners reported no remaining Pfizer position as of Q2 2018 after selling out during the quarter.
  • ARS Investment Partners sold 559,685 Pfizer shares in Q2 2018, an estimated $18.8M.
  • ARS Investment Partners first reported a position in Pfizer in Q4 2016 and held it in 6 quarters.
  • ARS Investment Partners's Pfizer position peaked at $18.8M in Q1 2018.
  • 2,204 funds tracked by Wall St. Rank held Pfizer as of Q2 2018.

Based on ARS Investment Partners's 13F filing for Q2 2018, filed 13 Aug 2018.